Context: Glucagon-like peptide-1 receptor agonists are popular antidiabetic drugs with potent glucoselowering effects and low risk of hypoglycemia. Animal experiments and human data indicate that tolerance develops toward at least some of their effects (e.g., gastric motility). Whether tolerance develops toward the glucose-lowering effect of glucagon-like peptide-1 receptor agonists has never been formally tested.
G lucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a popular tool for the treatment of type 2 diabetes. This drug class has proven to be effective and safe in lowering blood glucose level, hence in many guidelines, they are placed as a possible secondline option after metformin (1, 2) . The key benefits of GLP-1 RAs include low risk of hypoglycemia and modest weight loss with concomitant decrease in liver fat (3, 4) . Meanwhile, the counterregulatory hormonal mechanisms against hypoglucemia remain largely intact (5) . Interestingly, GLP-1 RAs seem to affect both peripheral and central targets. The appetite-suppressing and weight-reducing effects of GLP-1 analogs are a combination of GLP-1 receptor effects on the vagus nerve and in the area postrema; in addition, the underlying nucleus of the solitary tract (6) and administration of exenatide has been demonstrated to reduce food-induced brain responses (7) . Meanwhile, patients with type 2 diabetes may have decreased expression of GLP-1 receptors in the hypothalamus (8) .
Unlike many other antidiabetic drug classes, distinct GLP-1 RAs have different therapeutic profiles, mostly because of their different pharmacokinetic properties. The most remarkable side effects are gastrointestinal, although these subside with prolonged treatment (9) . One of the side effects of GLP-1 RA administration is decreased gastric motility (10) . Interestingly, it has been demonstrated that tolerance to that effect develops with liraglutide treatment but not with the shorter acting molecule, exenatide (11) . Furthermore, it is well known that most side effects, such as nausea and vomiting, subside with prolonged treatment (3). Because there is clear evidence that some effects of GLP-1 RAs are subject to the development of tachyphylaxis/tolerance, it is logical to ask whether the core effect of these drugs on glucose regulation may also be affected. Our previous studies in mice have indicated that GLP-1 RAs lower blood glucose level in a more robust manner after acute administration than after chronic dosing (12, 13) . Likewise, a recent study demonstrated that liraglutide lost efficacy after prolonged treatment in a humanized mouse model generated by intraocular islet transplantation (14) . Whether tolerance develops toward the glucose-lowering effect of GLP-1 RAs has never been formally tested. If the main therapeutic effect proves to be subject to the development of tolerance, treatment regimens may need to be adjusted to avoid loss of effect. We have conducted a clinical trial in healthy volunteers to address the possibility that tolerance develops toward the glucose-lowering effect of GLP-1 RAs.
Subjects and Methods

Study design
The study was a single group, open-label clinical trial. The primary purpose of the study was to investigate the development of tolerance to the glucose-lowering effect of liraglutide after chronic administration in healthy subjects. The primary end point was a change in the dose-response relationship between calculated insulin secretion rate (ISR) and blood glucose level, expressed as the slope of these curves.
Participants
Ten healthy volunteers were recruited. The inclusion criteria were as follows: (1) age 18 to 50 years and (2) body weight 50 to 100 kg. The exclusion criteria were as follows: (1) underlying chronic illnesses; (2) use of daily medications; (3) pregnancy or lactation; or (4) fasting glucose . 6 mmol/L. Each volunteer read and signed a written informed consent form and received thorough training about handling and using the liraglutide injection device.
Study procedures
Liraglutide pharmacodynamic effects were evaluated during a graded glucose infusion test (GGIT). Each subject underwent the test three times: the first was to assess the subject's normal state; the second to measure acute effects of the drug; and the third to test for chronic effects. The study design made it possible to use every participant as his or her own control. Subjects received treatment with liraglutide at a dose of 0.6 mg for 21 consecutive days. Liraglutide was selfadministered subcutaneously in the stomach area using prefilled injection pens and NovoFine needles (Novo Nordisk, Bagsvaerd, Denmark) once daily between 9 PM and 11 PM. Seven days before the initiation of treatment, the first GGIT was performed. The second GGIT test was performed 12 hours after the first liraglutide injection, and the third GGIT was performed 12 hours after the last liraglutide injection.
GGITs were carried out in the morning between 8 AM and 10 AM. Subjects were asked to fast for 12 hours before the beginning of the test and to avoid extreme physical activity during the previous day. A peripheral venous catheter was placed in both arms; one was used to obtain blood for analysis and the other was used to administer the glucose infusion. Two blood samples were taken (10 minutes apart) for baseline levels of glucose and hormones. An intravenous infusion of 20% glucose was then started at the rate of 1 mg/kg/min, followed by 5, 9, and 12 mg/kg/min. Each rate was sustained for 40 minutes; the total duration of the infusion was 160 minutes. Blood samples for glucose and C-peptide measurement were drawn every 20 minutes. During the test, study subjects were in a semisupine position, avoided physical activity, and did not eat or drink.
Materials
Commercially available liraglutide solution (Victoza, Novo Nordisk) was used. During GGIT, 20% glucose solution (Braun, Meldbungen, Germany) was used.
Calculations
The ISR was calculated for each time interval during the GGIT, using the computer program ISEC, version 3.4, obtained from the Hovorka and colleagues (15) . This program calculates prehepatic insulin secretion from plasma C-peptide measurements using a regression model to derive parameters of C-peptide kinetics from a subject's sex, type (normal, obese, noninsulin-dependent diabetes mellitus), age, weight, and height (16) . The relationship between glucose and ISR was used to describe the b-cell responsiveness to glucose. Mean ISRs were plotted against the corresponding glucose level, thereby establishing a dose-response relationship between the variables. The responsiveness to glucose was expressed as the slope of the linear regression line relating ISR and plasma glucose concentration.
Laboratory analysis
In the clinical trial, all laboratory analyses were carried out by the accredited laboratory of Tartu University Hospital. Glucose was measured using the enzymatic reference method with hexokinase (Cobas Glucose HK test; Roche Diagnostics GmbH, Mannheim, Germany). C-peptide was measured using an electrochemiluminescence immunoassay (Cobas C-peptide immunoassay, Roche Diagnostics GmbH).
Statistics
Data are presented as mean 6 standard error of the mean. A P value of , 0.05 was considered statistically significant. Data were statistically examined using one-way analysis of variance. Duncan multiple range post hoc test was used when applicable after statistically significant analysis of variance. STATISTICA 7 (StatSoft, Bedford, UK) was used for statistical analysis. Regression analysis was performed, and slope between the ISR and glucose relationship was calculated in R, version 3.2.5, using the ggplot2 package (R Foundation for Statistical Computing, Vienna, Austria). Area under the curve (AUC) was calculated using the trapezoidal method using GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA).
Study approval
This clinical trial was approved by the Research Ethics Committee of the University of Tartu (236/T-10) and the Estonian Agency of Medicines (RKU-4/18). All clinical investigations were conducted according to the principles of the Declaration of Helsinki, and all study subjects provided written informed consent before their inclusion in the study.
Results
Effect of liraglutide remained unaltered during the 3-week treatment in healthy volunteers
We conducted a small clinical study to test whether tolerance develops in humans. Ten healthy volunteers were recruited. The baseline characteristics of study participants are given in Table 1 . Three different GGITs were conducted on every participant to evaluate the effect of acute and chronic liraglutide treatment compared with no treatment conditions. All tests were carried out under the same conditions. As expected, treatment with liraglutide significantly lowered glucose levels and raised C-peptide levels and ISR during the GGIT [ Fig. 1(A-C) ]. The glucose AUCs for control, acute, and chronic administration were 1244 6 65, 849 6 48 (P , 0.05 vs control), and 865 6 60 mmol/L 3 160 minutes (P , 0.05 vs control). The corresponding AUCs for C-peptide were 257 6 30, 414 6 41 (P , 0.05 vs control), and 419 6 47 nmol/L 3 160 minutes (P , 0.05 vs control). Thus, for all parameters, chronic liraglutide treatment was as effective as acute treatment. Slope values of calculated ISR vs blood glucose level were control group, 1.6 6 0.7; acute group, 8.4 6 2.7 (P . 0.05 vs control); and chronic group, 6.8 6 2.2 (P . 0.05 vs control). Hence, the primary end point (ISR/glucose slope) of the study did not change after chronic administration of drug.
Discussion
GLP-1 RAs are a heterogenous group of antidiabetic drugs. The differences within drug class are exemplified by recent studies demonstrating variable results in cardiovascular end point trials of lixisenatide and liraglutide (17, 18) . There are several studies demonstrating tachyphylaxis with prolonged use of GLP-1 and long-acting GLP-1 agonists in case of gastric emptying (11, 19, 20) . Whether tachyphylaxis may modulate the insular effects of GLP-1 RA-s has been obscure. We report here a pilot clinical study testing whether tolerance toward glucose-lowering effect develops in humans. Ten healthy volunteers were treated with a low dose of liraglutide (0.6 mg subcutaneously) for 3 weeks and insulin secretion parameters were measured by conducting GGIT. The drug was administered 12 hours before testing because the maximum plasma concentration after liraglutide As expected, treatment with liraglutide lowered glucose levels and raised C-peptide levels and ISR during the GGIT. For all parameters, chronic liraglutide treatment was as effective as acute treatment. Hence, the primary end point (ISR/glucose slope) of the study did not change after chronic administration of drug; thus, we have demonstrated in healthy volunteers that tolerance does not develop toward the glucose-lowering effect of liraglutide after 3 weeks of treatment.
However, there are some limitations that are important to address. First, the dose of liraglutide used was lower than the usual clinical dose of 1.2 mg/d. Stepwise introduction of the drug is used in clinical practice to ease gastrointestinal side effects. Such an approach would obscure the measurement of tolerance development; therefore, flat dosing was used in our study. Because the effect of the drug on glucose parameters and insulin release was robust in our experiment, the dose used does not seem to be a major concern. Second, the study used nonobese healthy volunteers instead of type 2 diabetes patients. It would be challenging to test this hypothesis in diabetes patients because liraglutide-induced improvement in glucose levels may enhance b-cell function and thus mask the possible development of tolerance. Although there have been speculations whether GLP-1 RAs may directly improve the function of b cells, the clinical trial data in early type 2 diabetes patients did not support this hypothesis (22) . Third, the treatment time was 3 weeks, and one may speculate that a longer period of treatment may be needed to induce tolerance. Last, the number of participants was too small to examine possible sex effect and all participants were Caucasians.
Despite these limitations, we find that our results largely refute the hypothesis of tolerance development with prolonged liraglutide use in humans. It remains unclear whether the results can be generalized to other GLP RAs.
In conclusion, we have demonstrated that the GLP-1 RA, liraglutide, does not induce tolerance toward its glucose-lowering effect in healthy nonobese humans after 21 days of treatment.
